A series of generics of Boehringer Ingelheim Korea’s antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) seem to be receiving the market authorization one after another.

On Mar. 3, South Korea’s Ministry of Food and Drug Safety (MFDS) authorized Korea Prime Pharm’s Empazin 10 mg and 20 mg tablets.

As a result, three South Korean companies—Kukje Pharma, Dongkoo Bio & Pharma and Korea Prime Pharm—have Jardiance generics ready for the market.

The health authority green lit Kukje Pharma and Dongkoo Bio & Pharma’s Jardiance generics, Glinace and Empance, on Feb. 24. These were the first Jardiance generics to be approved i